高雄市生物科技發展協會|http://www.khba.org.tw
會員登入
記住帳號 自動登入
會員名錄
各式辦法
下載專區
留言板
您目前的位置:首頁 / 活動與新訊
Novartis drug cut death risk by 35 pct in gene mutation breast cancer
活動日期:2018.11.02
2018.11.02  

Novartis drug cut death risk by 35 pct in gene mutation breast cancer

https://finance.yahoo.com/news/novartis-drug-cut-death-risk-143001227.html

By John Miller
ZURICH, Oct 20 (Reuters) - An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.
The Swiss drugmaker's BYL719, a so-called PI3K inhibitor also known as alpelisib, combined with hormone therapy fulvestrant boosted median progression-free survival (PFS) to 11 months, up from 5.7 months for patients who got only hormone therapy, the company said on Saturday.
BYL719 plus fulvestrant cut risk of death or progression in those patients by an estimated 35 percent, Novartis said.
Novartis said earlier this year that this study, called SOLAR-1, of hormone receptor positive, HER2- breast cancer with mutations of the PIK3CA gene showed that YL719 helped patients.
But this specific benefit data is being released on Saturday at the European Society for Medical Oncology's annual conference in Munich.
Even though PIK3CA mutations are the most common genetic change in hormone-receptor positive breast cancer, trials of agents seeking to put a brake on this pathway to tumour growth have largely disappointed including on safety issues.
Other drugmakers including Roche have seen similar investigational medicines stumble, making Novartis's progress here hopeful news, doctors involved in the trial said.
"The results of SOLAR-1 are the most encouraging observed to date from a trial evaluating a PI3K inhibitor" for patients with this kind of breast cancer, said Fabrice Andre, a professor at France's Institut Gustave Roussy.
"These data have the potential to allow physicians to address an unmet need in this patient population by using a biomarker-driven treatment to inform their sequencing decisions," Andre added.
Like other companies, Novartis is seeking to personalise treatment for cancer patients by using biomarkers like those showing PIK3CA gene mutations to help guide treatment.


TALKS WITH REGULATORS
This week, Novartis signed a deal to have Roche unit Foundation Medicine provide genomic profiling of patient samples taken from Novartis' clinical oncology trials. Other cancer drugmakers like Bristol-Myers Squibb and Merck also have Foundation deals.
Samit Hirawat, head of Novartis's cancer drug development, said in an interview the side-effects profile of alpelisib held up.
"We don't see as much diarrhea, we do not have CNS (central nervous system) side effects, we do not have the liver effects," he said.
Novartis plans to file with regulators for approval of the drug this year, Hirawat said, adding he also has strategies to broaden the indication, including tough-to-treat triple-negative breast cancer.
"PIK3CA mutations are present in many other tumour types," Hirawat said. "There is a larger programme we are putting into place." (Reporting by John Miller. Editing by Jane Merriman)

共有310筆資料 頁數: 第8頁(共16頁)
編號 標題 新增日期
1 全球首例 黃斑部退化裝仿生眼 2015.07.23
2 鼻涕倒流 小心變慢性病 2015.07.13
3 健康殺手 胰臟癌 2015.07.13
4 《中英對照讀新聞》Chocolate may be good for your heart, st.. 2015.07.09
5 新化學物質及既有化學物質資料登錄法規及系統說明會 2015.06.25
6 制酸處方胃藥 腸胃感染風險多4倍卅抗生素、止痛藥同樣也有高風險 2015.06.24
7 中原大學創新育成中心的邀約 – 辦裡泰國投資商機說明會 (生技.. 2015.06.04
8 10大死因 癌症蟬聯33年第一 2015.06.18
9 吃素餓死癌腫瘤 偏方害死人 2015.06.09
10 治大腸激躁症 中醫依體質配藥 2015.06.05
11 治療C肝有解 國衛院研發本土新藥 2015.06.04
12 青年肝癌猝逝罕見 醫師:應與基因有關 2015.06.02
13 人類蛋白質新突破! 建中生找到「關鍵」登《Nature》 2015.05.28
14 吃菠菜綠花椰菜 可降低白內障風險 2015.05.27
15 研究:青春期肥胖 罹大腸癌機率多2.38倍 2015.05.27
16 缺藥通報件數 4年暴增10倍 2015.05.07
17 中醫疏肝解壓 擺脫惱人腸躁症 2015.05.06
18 選抗老化中草藥強攻機能保健品及新藥開發 陽明吳榮燦創立長宏.. 2015.04.28
19 The Future of Cancer: Closer to a Cure 2015.04.28
20 台大研究 不切片可發現癌細胞 2015.04.22
上一頁  1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16  下一頁
版權所有©2006 高雄市生物科技發展協會 所有文字、資料禁止轉用
地址:高雄市中正一路120號14樓之3 TEL:(07)591-9569 / FAX:(07)591-9018 / e-mail: khba.tw@gmail.com
累積進站人數:2896643